Chidumwa, Glory
Chimbindi, Natsayi
Herbst, Carina
Okeselo, Nonhlanhla
Dreyer, Jaco
Zuma, Thembelihle
Smith, Theresa
Molina, Jean-Michel
Khoza, Thandeka
McGrath, Nuala
Seeley, Janet
Pillay, Deenan
Tanser, Frank
Harling, Guy
Sherr, Lorraine
Copas, Andrew
Baisley, Kathy
Shahmanesh, Maryam http://orcid.org/0000-0001-7129-8535
Funding for this research was provided by:
National Institutes of Health (5R01MH114560-03)
Wellcome Trust (082384/Z/07/Z, 210479/Z/18/Z)
Bill and Melinda Gates Foundation (3ie international initiative for impact evaluation)
National Institute for Health Research (RP-2017-08-ST2-008)
Article History
Received: 10 February 2022
Accepted: 17 February 2022
First Online: 7 March 2022
Declarations
:
: Ethical approval has been obtained the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00000473/2019) and UCL Research Ethics Committee (5672/003). All staff (including peer navigators) were provided with training on research ethics including confidentiality, voluntary participation and good clinical practice. Written informed consent is obtained from all participants aged 18–29 years. For those aged 16–17 we obtain written infomed assent from participants and written informed consent from their parents or guardian. This is an effectiveness trial of different models of service delivery and all tests and drugs used are approved for clinical use in South Africa. All clinical care follows South African clinical guideline. The risk of harm is anticipated to be low.
: Not applicable.
: The authors declare that they have no competing interests.